These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27983837)

  • 1. Prediction of Protein Kinase-Ligand Interactions through 2.5D Kinochemometrics.
    Bosc N; Wroblowski B; Meyer C; Bonnet P
    J Chem Inf Model; 2017 Jan; 57(1):93-101. PubMed ID: 27983837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based quantitative structure-activity relationship studies of checkpoint kinase 1 inhibitors.
    Du J; Xi L; Lei B; Lu J; Li J; Liu H; Yao X
    J Comput Chem; 2010 Nov; 31(15):2783-93. PubMed ID: 20839304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
    Ung PM; Schlessinger A
    ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
    Simard JR; Rauh D
    Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
    Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
    Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative computer-aided methods for the discovery of new kinase ligands.
    Abuhammad A; Taha M
    Future Med Chem; 2016 Apr; 8(5):509-26. PubMed ID: 27105126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity reagents that target a specific inactive form of protein kinases.
    Ranjitkar P; Brock AM; Maly DJ
    Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR models for predicting the similarity in binding profiles for pairs of protein kinases and the variation of models between experimental data sets.
    Sheridan RP; Nam K; Maiorov VN; McMasters DR; Cornell WD
    J Chem Inf Model; 2009 Aug; 49(8):1974-85. PubMed ID: 19639957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinome-Wide Profiling Prediction of Small Molecules.
    Sorgenfrei FA; Fulle S; Merget B
    ChemMedChem; 2018 Mar; 13(6):495-499. PubMed ID: 28544552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics.
    Subramanian V; Prusis P; Pietilä LO; Xhaard H; Wohlfahrt G
    J Chem Inf Model; 2013 Nov; 53(11):3021-30. PubMed ID: 24116714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues.
    Bosc N; Wroblowski B; Aci-Sèche S; Meyer C; Bonnet P
    ACS Chem Biol; 2015 Dec; 10(12):2827-40. PubMed ID: 26411811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
    Dar AC; Shokat KM
    Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structural atlas of kinases inhibited by clinically approved drugs.
    Wang Q; Zorn JA; Kuriyan J
    Methods Enzymol; 2014; 548():23-67. PubMed ID: 25399641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
    Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
    J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
    Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
    Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
    Martin E; Mukherjee P
    J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.